| Literature DB >> 29155240 |
Ali Alaseem1, Khalid Alhazzani2, Priya Dondapati3, Saad Alobid2, Anupam Bishayee4, Appu Rathinavelu5.
Abstract
Matrix metalloproteinases (MMPs) are members of zinc-dependent endopeptidases implicated in a variety of physiological and pathological processes. Over the decades, MMPs have been studied for their role in cancer progression, migration, and metastasis. As a result, accumulated evidence of MMPs incriminating role has made them an attractive therapeutic target. Early generations of broad-spectrum MMP inhibitors exhibited potent inhibitory activities, which subsequently led to clinical trials. Unexpectedly, these trials failed to meet the desired goals, mainly due to the lack of efficacy, poor oral bioavailability, and toxicity. In this review, we discuss the regulatory role of MMPs in cancer progression, current strategies in targeting MMPs for cancer treatment including prodrug design and tumor imaging, and therapeutic value of MMPs as biomarkers in breast, lung, and prostate cancers.Entities:
Keywords: Biomarker; Cancer; Matrix metalloproteinase; Matrix metalloproteinase inhibitors
Mesh:
Substances:
Year: 2017 PMID: 29155240 DOI: 10.1016/j.semcancer.2017.11.008
Source DB: PubMed Journal: Semin Cancer Biol ISSN: 1044-579X Impact factor: 15.707